FLT4 Amplification

CI-VAR-00000233Explore in graph →CIViC 2205

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Angiosarcoma1
FLT4 Amplification	Pazopanib	Predictive	C	Supports Sensitivity Response	3	submitted	EID5911 One patient with angiosarcoma was initially treated with sorafenib, an inhibitor of VEGFR2, and developed progressive disease. The patient then received pazopanib, an inhibitor of VEGFR2 and VEGFR3 an… (full text at CIViC) PMID 27160228 · Ravi et al., 2016 · Open in CIViC	civic
Ewing Sarcoma1
FLT4 Amplification	Pazopanib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7539 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that respond… (full text at CIViC) PMID 28377484 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.